JMP Securities reiterates an Outperform rating on Synta tgt 18
Outlook for Synta Pharma ganetespib still positive, says JMP Securities
After Infinity's (INFI) Hsp90 inhibitor, retaspimycin, failed its Phase II NSCLC study, JMP Securities notes that retaspimycin and Synta's (SNTA) ganetespib share a similar mechanism of action. Nonetheless JMP Securities reports that the drugs address patients with different types of cancers, and the firm thinks that ganetespib is more potent than retaspimycin. JMP Securities reiterates an Outperform rating on Synta.